Journal_1_2014_final_WEB

Science, Practice and Education
Figure 1:
a) Ulcer appearance at baseline;
b) plasma rich in growth factors (PRGF)-membrane;
c) wound appearance after 3 weeks of treatment;
d) wound appearance after 4 weeks of treatment.
a
b
and wound dressings were carried out with 7-day intervals.
During wound dressing, the PRP clot was covered
with atraumatic Atrauman Ag silver-impregnated wound
dressing and gauze pads. The duration of treatment was
21 days and included three dressings using PRP. Treatment
resulted in complete re-epithelialisation of the ulcer by day
28 of the treatment (Fig. 1).
Discussion
PRP therapy is the preferable treatment option in patients
with chronic non-healing wounds of different aetiology
and localisation, particularly when other more conventional
therapies lack evidence of effectiveness or when radical
surgical treatment is not possible or contraindicated.
The use of PRP not only reduces the duration and
cost of treatment but also decreases the number of dressings,
shortens the inpatient hospital stay (because most
of the patients can be followed up on an outpatient basis
with intervals between dressing changes of 6-8 days) and
improves the patients’ quality of life. Notably, all of the
patients demonstrated reduced sensitivity to pain after the
PRP treatment had started.
The advantages of using an autologous PRP include
no risk of disease transmission, introduction of growth
factors and cytokines directly into the wound, restoration
of metabolic processes, neoangiogenesis, improvement of
cellular metabolism and activation of local immunity [30-32] .
m
c
d
References
1. Marx R.E. Radiation injury to tissue. // Kindwall E.R. (ed.)
Hyperbaric Medicine Practice. Flagstaff, AZ: Best Publishing
Company. – 1994. – P.447-504.
2. Anitua E. Plasma rich in growth factors: Preliminary results of
use in the preparation of future sites for implants. // Int J Oral
Maxillofac Implants. – 1999. – # 14. – P.529-535.
3. Akhmerov R.R., Zarudiy R.F., Bochkova O.I., (Korotkova),
Rychkova N.N. Plasmolifting («Plasmolifting TM ») in the
treatment of age-related skin atrophy using the platelet-rich
autoplasma. // Aesthetic medicine (Russian), vol. X. – 2011.
– no. 2. – P.181-187.
4. Plasmolifting («Plasmolifting TM ») technique – a guidebook for
physicians. / R.R. Akhmerov, R.F. Zarudiy, Eds. (Russian).
– M. – 2012. – 23 pp.
5. Marx R.E., DDS. Platelet-reach plasma (PRP): what is PRP
and what is not PRP? // Implantdentistry. - 2001. - Vol.10,
No.4. – P.225-228.
6. Chekalina E.N. Role of platelet concentrate in tissue
reparation and regeneration. // «Dental South» (Russian). –
2005. - no. 3(32). – P.23.
7. Caplan A.I., Correa D. J. PDGF in Bone Formation and
Regeneration: New Insights into a Novel Mechanism
Involving MSCs. // Orthop Res. – 2011. – Vol. 29, no. 12. -
P.1795-1803.
8. De la Riva B., Sánchez E., Hernández A., Reyes R., Tamimi F.,
López-Cabarcos E., Delgado A., Evora C. Local controlled
release of VEGF and PDGF from a combined brushitechitosan
system enhances bone regeneration. // J Control
Release. - 2010. - Vol. 143, no. 1. - P.45-52.
9. Committee on Research, Science, and Therapy of the
American Academy of Periodontology. The potential role of
growth and differentiation factors in periodontal regeneration.
// Periodontol. – 1996. - no. 67. – P.545-553.
10. Dennison DK, Vallone DR, Pinero GJ, et al. Differential effect
of TGF-Bland PDGF on prolife ration of periodontal ligament
cells and gin-giva l fibroblasts. // Periodontol. – 1994. - no.
65. – P.641-648.
40
EWMA Journal 2014 vol 14 no 1